13F-HR/A filed by Boxer Capital Management, LLC
Boxer Capital Management, LLC filed this 13F-HR/A for the quarter ended 2025-06-30, filed 2026-02-17, with 20 holding rows worth $198,660,671.
- Accession
- 0002018299-26-000004
- Filer
- CIK 2018299
- Filed
- 2026-02-17
- Accepted by EDGAR
- acceptance time not in the bulk data set
- Ingested
- Source
- SEC quarterly data set
13F report for Q2 2025
A holdings report, amendment of type restatement, 20 entries on the cover page, a total value of $198,660,671 stated on the cover page (in dollars after the unit check, H1), rows summing to $198,660,671 with VALUE read as dollars as filed, 13F file number 028-25329. The quarter's positions are built on this report. The resolved quarter.
The information table after summing rows of one CUSIP and put or call (H4), with the CUSIP and issuer name as filed. Values in dollars after the unit check (method).
| Issuer as filed | CUSIP | Class | Amount | Value | Value read as | Type |
|---|---|---|---|---|---|---|
| TANGO THERAPEUTICS INC | 87583X109 | COM | 9,771,485 | $50,030,003 | dollars as filed | |
| REVOLUTION MEDICINES INC COM | 76155X100 | Stock | 792,977 | $29,173,624 | dollars as filed | |
| REPLIMUNE GROUP INC | 76029N106 | COMMON STOCK | 2,211,341 | $20,543,358 | dollars as filed | |
| MERUS N V | N5749R100 | COM | 365,000 | $19,199,000 | dollars as filed | |
| KYMERA THERAPEUTICS INC | 501575104 | COM | 432,010 | $18,852,916 | dollars as filed | |
| UNIQURE NV | N90064101 | SHS | 899,500 | $12,539,030 | dollars as filed | |
| ITEOS THERAPEUTICS INC | 46565G104 | COM | 825,000 | $8,225,250 | dollars as filed | |
| UROGEN PHARMA LTD | M96088105 | COMMON STOCK | 575,000 | $7,877,500 | dollars as filed | |
| AMYLYX PHARMACEUTICALS INC | 03237H101 | COM | 1,225,000 | $7,852,250 | dollars as filed | |
| CRESCENT BIOPHARMA INC | G2545C104 | COMMON STOCK | 453,686 | $7,322,492 | dollars as filed | |
| PROTAGONIST THERAPEUTICS | 74366E102 | COM | 60,000 | $3,316,200 | dollars as filed | |
| NEKTAR THERAPEUTICS | 640268306 | COMMON STOCK | 125,000 | $3,230,000 | dollars as filed | |
| KODIAK SCIENCES INC | 50015M109 | COM | 750,000 | $2,797,500 | dollars as filed | |
| CIDARA THERAPEUTICS INC | 171757206 | COM NEW | 55,000 | $2,679,050 | dollars as filed | |
| NURIX THERAPEUTICS INC | 67080M103 | COMMON STOCK | 175,000 | $1,993,250 | dollars as filed | |
| Instil Bio Inc | 45783C200 | COM NEW | 70,700 | $1,472,681 | dollars as filed | |
| KALVISTA PHARMACEUTICALS INC | 483497103 | COM | 93,400 | $1,055,887 | dollars as filed | |
| SAREPTA THERAPEUTICS INC | 803607100 | COM | 25,000 | $427,500 | dollars as filed | |
| NUVATION BIO INC | 67080N119 | WARR | 266,666 | $71,973 | dollars as filed | |
| SURROZEN INC | 86889P117 | *W EXP 08/01/203 | 66,666 | $1,207 | dollars as filed |
Amendment chain
| Filing | Role | Filed | Accepted | Ingested |
|---|---|---|---|---|
| 13F-HR 0002018299-25-000005 | superseded | 2025-08-14 | acceptance time not in the bulk data set | |
| 13F-HR/A 0002018299-26-000004 | this filing | 2026-02-17 | acceptance time not in the bulk data set |